In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

ArQule gets $75mm up front in two new deals with Daiichi; certain rights returned to ArQule

Executive Summary

ArQule (oncology therapeutics) and Daiichi Sankyo (Japanese pharmaco developing treatments for cardiovascular diseases, diabetes, autoimmune disorders, cancer, and infections) have entered into two cancer deals that together provide ArQule with $75mm up front and the potential for up to $560mm in milestones.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register